Zacks Investment Research lowered shares of Prima BioMed Ltd. (NASDAQ:PBMD) from a hold rating to a sell rating in a research note released on Tuesday morning.

According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “

Several other research analysts also recently commented on the stock. FBR & Co set a $6.00 price objective on shares of Prima BioMed and gave the stock a buy rating in a report on Thursday, September 8th. Roth Capital reaffirmed a buy rating and issued a $6.00 price objective on shares of Prima BioMed in a report on Friday, August 26th. Maxim Group reaffirmed a buy rating and issued a $5.00 price objective on shares of Prima BioMed in a report on Tuesday, July 12th. Finally, HC Wainwright reaffirmed a buy rating on shares of Prima BioMed in a report on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $4.20.

Prima BioMed (NASDAQ:PBMD) opened at 0.8889 on Tuesday. Prima BioMed has a one year low of $0.72 and a one year high of $1.54. The stock’s 50 day moving average is $0.87 and its 200 day moving average is $0.95. The firm’s market capitalization is $61.09 million.

Prima BioMed Company Profile

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.

5 Day Chart for NASDAQ:PBMD

Get a free copy of the Zacks research report on Prima BioMed (PBMD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with's FREE daily email newsletter.